James S. Duncan
Department of Cancer Research
Fox Chase Cancer Center
United States of America
Biography
James S. Duncan,Educational Background: PhD, Biochemistry, University of Western Ontario, London, ON, 2008. BSc, Biochemistry, University of Western Ontario, London, ON, 2005. Honors & Awards: Canadian Institutes of Health Research Postdoctoral Fellowship -2009-2012. Collip Award for Top Thesis in School of Medicine and Dentistry- 2009. Canadian Institutes of Health Research (CIHR-CGS) - 2005-2008 .
Research Interest
Exploring the cancer kinome through chemical proteomics. Unlocking the therapeutic potential of the "untargeted kinome." Designing novel combination therapies for the treatment of cancer.
Publications
-
Gaponova, A. V., Nikonova, A. S., Deneka, A. Y., Kopp, M. C., Kudinov, A. E., Skobeleva, N., ... & Duncan, J. S. (2016). A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clinical Cancer Research, 22(20), 5120-5129.
-
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., ... & Usary, J. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell, 149(2), 307-321.
-
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., ... & Usary, J. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell, 149(2), 307-321.
